{"denoms":[{"counts":[{"groupId":"BG000","value":"24"}],"units":"Participants"}],"groups":[{"description":"Bendamustine: On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\\^2, and then to 60 mg/m\\^2 bendamustine on days 1 and 4 if ANC is not \\>1 x 10\\^9/L and platelets are not \\>50 x 10\\^9/L on day 1 of each cycle.\n\nPatients will be treated until disease progression after at least one cycle of treatment.\n\nBortezomib: On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\\^2 followed by bendamustine given at 90 mg/m\\^2. Patients will be dose reduced to 75 mg/m\\^2, and then to 60 mg/m\\^2 bendamustine on days 1 and 4 if ANC is not \\>1 x 10\\^9/L and platelets are not \\>50 x 10\\^9/L on day 1 of each cycle.\n\nPatients will be treated until disease progression after at least one cycle of treatment.","id":"BG000","title":"Bortezomib and Bendamustine"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}]}